Home > Insider Trading > Latest 13D and 13G Filings > 13D Filing (0001171520-22-000347)

Filing Details

Accession Number:: 0001171520-22-000347
Form Type:: 13D Filing
Publication Date:: 2022-05-24 20:00:00

Filed By:: Singer Julian D.
Company:: Gyre Therapeutics Inc. (NASDAQ:GYRE)
Filing Date:: 2022-05-25
SEC Url:: 13D Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
JDS1	0	2,014,832	0	2,014,832	2,014,832	6.4%
CCUR Holdings, Inc	0	883,255	0	883,255	883,255	2.8%
CIDM II	0	883,255	0	883,255	883,255	2.8 %
Julian D. Singer	0	2,014,832	0	2,014,832	2,014,832	6.4%
David S. Oros	388,600	0	388,600	0	388,600	1.2 %
Shelly C. Lombard	0	0	0	0	0	0%
Matthew Stecker	0	0	0	0	0	0%
Igor Volshteyn	0	0	0	0	0	0%

Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D/A

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

(Amendment No. 13)1

Catalyst Biosciences, Inc.
(Name of Issuer)

Common Stock, par value $0.001 per share
(Title of Class of Securities)

	14888D208
	(CUSIP Number)

JULIAN D. SINGER JDS1, LLC 2200 Fletcher Avenue, Suite 501 Fort Lee, New Jersey 07024 (201) 592-3400
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

	May 24, 2022
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box